Oculus Issues Chinese Commercialization Plans For Microcyn Technology
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Oculus will formally begin commercializing its Microcyn technology-based Dermacyn products in China in cooperation with its Chinese partners China Bao Tai Investment and Sinopharm, the company announced May 5